Clinical Laserthermia Systems AB Class B (DE:LS60)
FRANKFURT:LS60
LS60 Stock Chart & Stats
€0.59
<€0.01(0.74%)
At close: 4:00 PM EST
€0.59
<€0.01(0.74%)
Day’s Range― - ―
52-Week Range€0.18 - €1.16
Previous CloseN/A
Volume0.00
Average Volume (3M)75.00
Market Cap
€13.40M
Enterprise Value€98.74M
Total Cash (Recent Filing)€21.55M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta3.80
Next Earnings
May 15, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding31,163,593
10 Day Avg. Volume175
30 Day Avg. Volume75
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)2.55
Price to Sales (P/S)10.18
P/FCF Ratio-4.96
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)€5.07M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Clean Balance SheetA near-zero debt position reduces financial risk and interest burden, giving management flexibility to finance operations, R&D or clinical trials through equity or grants. This balance-sheet strength extends runway versus highly leveraged peers and supports strategic options over months.
Recurring Revenue PotentialThe business model includes recurring consumables and services tied to installed systems, a durable medtech revenue pattern. As installed base and procedure volumes grow, consumables and service revenue can scale with higher gross margins and provide predictable cash flow over time.
Improving Loss TrendA narrowing EBIT loss signals improving operating efficiency or revenue/mix effects. If this trend persists, it can meaningfully reduce cash burn and extend financing runway, indicating early operational progress toward sustainable margins rather than one-off short-term moves.
Bears Say
Persistent Negative Cash FlowOperating and free cash flows are deeply negative and have been so across periods, implying continued reliance on external financing or equity. This structural cash burn limits investment capacity for commercialization, trials, and growth unless a durable turnaround or financing solution is secured.
Small, Declining Revenue And Negative MarginsFalling revenue combined with negative gross and very large net margins indicates weak market adoption, pricing or cost issues. These structural profitability problems mean the core unit economics are not yet viable and must improve for long-term sustainability.
Limited Commercial Scale & Unclear PartnershipsThe company’s small scale and lack of disclosed, material partnerships constrain market access and clinical adoption. Unclear partner commitments reduce visibility on validation and revenue support, limiting the installed-base growth needed to realize recurring consumables and service revenue.
LS60 FAQ
What was Clinical Laserthermia Systems AB Class B’s price range in the past 12 months?
Clinical Laserthermia Systems AB Class B lowest stock price was €0.18 and its highest was €1.16 in the past 12 months.
What is Clinical Laserthermia Systems AB Class B’s market cap?
Clinical Laserthermia Systems AB Class B’s market cap is €13.40M.
When is Clinical Laserthermia Systems AB Class B’s upcoming earnings report date?
Clinical Laserthermia Systems AB Class B’s upcoming earnings report date is May 15, 2026 which is in 50 days.
How were Clinical Laserthermia Systems AB Class B’s earnings last quarter?
Clinical Laserthermia Systems AB Class B released its earnings results on Feb 20, 2026. The company reported -€0.036 earnings per share for the quarter, missing the consensus estimate of N/A by -€0.036.
Is Clinical Laserthermia Systems AB Class B overvalued?
According to Wall Street analysts Clinical Laserthermia Systems AB Class B’s price is currently Overvalued.
Does Clinical Laserthermia Systems AB Class B pay dividends?
Clinical Laserthermia Systems AB Class B does not currently pay dividends.
What is Clinical Laserthermia Systems AB Class B’s EPS estimate?
Clinical Laserthermia Systems AB Class B’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Clinical Laserthermia Systems AB Class B have?
Clinical Laserthermia Systems AB Class B has 31,163,593 shares outstanding.
What happened to Clinical Laserthermia Systems AB Class B’s price movement after its last earnings report?
Clinical Laserthermia Systems AB Class B reported an EPS of -€0.036 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -23.125%.
Which hedge fund is a major shareholder of Clinical Laserthermia Systems AB Class B?
Currently, no hedge funds are holding shares in DE:LS60
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Clinical Laserthermia Systems AB Class B
Clinical Laserthermia Systems AB (publ) develops treatment tools for diseased tissue under the TRANBERG brand in Sweden. The company offers TRANBERG, a thermal therapy system designed to deliver laser energy to heat the target tissue. It also provides mobile laser unit, a controlling component with a wavelength of 1064 nanometers provides multiple options to control treatment. In addition, the company offers various gauge laser applicators, as well as provides temperature and treatment monitoring devices. Clinical Laserthermia Systems AB (publ) was incorporated in 2006 and is headquartered in Lund, Sweden.
Technical Analysis
SpectraCure AB
―
Luxbright AB
―
Scandinavian Real Heart AB
―
Nosa Plugs AB
―
Arcoma AB
―